Improving natural product research translation: From source to clinical trial

Barbara C. Sorkin, Adam J. Kuszak, Gregory Bloss, Naomi K. Fukagawa, Freddie Ann Hoffman, Mahtab Jafari, Bruce Barrett, Paula N. Brown, Frederic D. Bushman, Steven J. Casper, Floyd H. Chilton, Christopher S. Coffey, Mario G. Ferruzzi, D. Craig Hopp, Mairead Kiely, Daniel Lakens, John B. MacMillan, David O. Meltzer, Marco Pahor, Jeffrey PaulKathleen Pritchett-Corning, Sara K. Quinney, Barbara Rehermann, Kenneth D.R. Setchell, Nisha S. Sipes, Jacqueline M. Stephens, D. Lansing Taylor, Hervé Tiriac, Michael A. Walters, Dan Xi, Giovanna Zappalá, Guido F. Pauli

Research output: Contribution to journalReview article

Abstract

While great interest in health effects of natural product (NP) including dietary supplements and foods persists, promising preclinical NP research is not consistently translating into actionable clinical trial (CT) outcomes. Generally considered the gold standard for assessing safety and efficacy, CTs, especially phase III CTs, are costly and require rigorous planning to optimize the value of the information obtained. More effective bridging from NP research to CT was the goal of a September, 2018 transdisciplinary workshop. Participants emphasized that replicability and likelihood of successful translation depend on rigor in experimental design, interpretation, and reporting across the continuum of NP research. Discussions spanned good practices for NP characterization and quality control; use and interpretation of models (computational through in vivo) with strong clinical predictive validity; controls for experimental artefacts, especially for in vitro interrogation of bioactivity and mechanisms of action; rigorous assessment and interpretation of prior research; transparency in all reporting; and prioritization of research questions. Natural product clinical trials prioritized based on rigorous, convergent supporting data and current public health needs are most likely to be informative and ultimately affect public health. Thoughtful, coordinated implementation of these practices should enhance the knowledge gained from future NP research.

Original languageEnglish (US)
Pages (from-to)41-65
Number of pages25
JournalFASEB Journal
Volume34
Issue number1
DOIs
StatePublished - Jan 1 2020

Keywords

  • clinical predictive validity
  • dietary supplements
  • model systems
  • rigor and replicability
  • value of information

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Fingerprint Dive into the research topics of 'Improving natural product research translation: From source to clinical trial'. Together they form a unique fingerprint.

  • Cite this

    Sorkin, B. C., Kuszak, A. J., Bloss, G., Fukagawa, N. K., Hoffman, F. A., Jafari, M., Barrett, B., Brown, P. N., Bushman, F. D., Casper, S. J., Chilton, F. H., Coffey, C. S., Ferruzzi, M. G., Hopp, D. C., Kiely, M., Lakens, D., MacMillan, J. B., Meltzer, D. O., Pahor, M., ... Pauli, G. F. (2020). Improving natural product research translation: From source to clinical trial. FASEB Journal, 34(1), 41-65. https://doi.org/10.1096/fj.201902143R